Johnson & Johnson (JNJ)
Johnson & Johnson - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Johnson & Johnson - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General